ClearTrial to Demonstrate Software at the 3rd Annual Clinical Outsourcing World Conference
ClearTrial announced it will demonstrate its Clinical Trial Operations (CTO) software to an audience of more than 125 clinical outsourcing professionals at the 3rd Annual Clinical Outsourcing World conference in London. The event attracts biopharm companies from around the globe to hear outsourcing experts discuss strategic and operational challenges of partnering with CROs.
ClearTrial software is built on an activity-based or “project management” architecture, which enables the software to provide speed, accuracy, and flexibility to outsourcing groups and clinical operations. Supporting all outsourcing models and contract types, as well as 39 currencies and over 150 therapeutic indications, the software automatically calculates labor costs across 70 different countries.
Cubist Pharmaceuticals, Inc., a Massachusetts-based biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment, recently acquired the ClearTrial software, with a view to further enhance their clinical outsourcing efficiency.
“New clinical outsourcing models and alternatives that are in practice today have created much more complexity for our clinical trial planning and for optimizing our outsourcing needs,” said Dr. Santosh Vetticaden, Chief Medical Officer at Cubist. “We are looking forward to utilizing the capabilities of ClearTrial, to allow us to quickly compare cost scenarios for different approaches—fully outsourced, outsourced by function, independent contractors, and studies performed in whole or in part by internal Cubist personnel.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
